Strategy
MSTR
MARA Holdings
MARA
Petroleo Brasileiro SA Petrobras
PBR
NVIDIA
NVDA
Adobe
ADBE
US Stock MarketDetailed Quotes
GBIO Generation Bio
- 0.480
- -0.032-6.25%
Close Mar 14 16:00 ET
- 0.490
- +0.010+2.08%
Post 20:01 ET
32.16MMarket Cap-0.24P/E (TTM)
0.524High0.480Low944.77KVolume0.510Open0.512Pre Close468.57KTurnover1.94%Turnover RatioLossP/E (Static)67.01MShares4.65052wk High0.37P/B23.42MFloat Cap0.47252wk Low--Dividend TTM48.78MShs Float55.720Historical High--Div YieldTTM8.67%Amplitude0.472Historical Low0.495Avg Price1Lot Size
About Generation Bio Company
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Company Profile
SymbolGBIO
Company NameGeneration Bio
Listing DateJun 12, 2020
Issue Price19.00
Founded2016
CEODr. Geoffrey McDonough, M.D.
MarketNASDAQ
Employees174
Fiscal Year Ends12-31
Address301 Binney Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-655-7500
Websitehttp://www.generationbio.com
Company Executives
- Name
- Position
- Salary
- Dr. Geoffrey McDonough, M.D.
- President, Chief Executive Officer and Director
- 2.32M
- Dr. Phillip Samayoa, PhD
- Chief Scientific Officer
- --
- Yalonda Howze, J.D.
- Chief Legal Officer and Secretary
- 1.21M
- Kevin Conway
- Chief Financial Officer and Principal Accounting Officer
- --
- Antionette Paone, M.B.A.,M.S.
- Chief Operating Officer
- --
- Jason P. Rhodes
- Chairman of the Board
- 181.21K
- Anthony G. Quinn, Ch.B.,M.B.,PhD
- Independent Director
- 143.71K
- Dr. Jeffrey M. Jonas,M.D.
- Independent Director
- 140.21K
- Dannielle Appelhans
- Independent Director
- 140.21K
- Ronald H.W. Cooper
- Independent Director
- 144.21K
- Gustav A. Christensen
- Independent Director
- 143.71K
- Charles A. Rowland, Jr,M.B.A.
- Independent Director
- 151.21K
- Dr. Donald W. Nicholson, PhD
- Independent Director
- 143.71K
- Dr. Catherine Stehman-Breen, M.D.
- Independent Director
- 143.71K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.